Golbi SR 450 Tablet contains Ursodeoxycholic Acid 450 mg, a hydrophilic bile acid used primarily in the treatment of certain hepatobiliary disorders. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile and bile stones, thereby promoting the dissolution of cholesterol gallstones in patients with functioning gallbladders. Additionally, it exerts cytoprotective effects on hepatocytes by stabilizing cell membranes and reducing the toxic effects of hydrophobic bile acids. Golbi SR 450 is indicated for the management of primary biliary cholangitis, intrahepatic cholestasis, and the prevention of cholesterol gallstone formation. It is also employed as an adjunct therapy in various cholestatic liver diseases to improve liver function tests and alleviate symptoms such as pruritus. The sustained-release formulation ensures a controlled release of Ursodeoxycholic Acid, enhancing patient compliance and maintaining therapeutic plasma concentrations over an extended period. Dosage and duration of therapy should be individualized based on the patient’s clinical condition and response to treatment. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Golbi SR 450 should be used under medical supervision with regular monitoring of liver function and symptomatology to optimize therapeutic outcomes and minimize potential risks.